Revive Therapeutics (OTC:RVVTF) has provided an update on Phase 3 of its Bucillamine clinical trial. Bucillamine is a drug developed to treat coronavirus. There is the potential for Bucillamine to be eligible for funding from the federal government through Biomedical Advanced Research and Development Authority or BARDA for short.
BARDA has the potential to fund Revive, ultimately hastening the trial’s completion. BARDA might also provide additional funding to upgrade facilities that expedite Bucillamine’s production. There is even the potential for Revive’s efforts in the context of developing Bucillamine to result in the sale of the drug to the federal government.
